Osteochondropathy refers to a disease ("-pathy") of the bone and cartilage. However, it is more common to refer to these conditions as one of the following:

chondropathy (disease of the cartilage)
A bone disease is also called an "osteopathy", but because the term osteopathy is often used to describe a healthcare approach, use of the term can cause some confusion. See also
Osteochondrosis
Osteochondritis

References


== External links ==
In 2016, Impact Biomedicines acquired the rights to fedratinib from Sanofi and continued its development for the treatment of myelofibrosis and polycythemia vera. In January 2018, the drugs rights were transferred to Celgene with their purchase of Impact Biomedicines.Fedratinib was approved for medical use in the United States in August 2019.The U.S. Food and Drug Administration (FDA) granted the application for fedratinib priority review and orphan drug designations. The FDA granted the approval of Inrebic to Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation. References
External links
"Fedratinib". Drug Information Portal. U.S. National Library of Medicine. Clinical trial number NCT01437787 for "Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis (JAKARTA)" at ClinicalTrials.gov